Financials QuantRx Biomedical Corporation
Equities
QTXB
US74765N1090
Advanced Medical Equipment & Technology
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.004 USD | -.--% | -.--% | -49.37% |
Valuation
Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
---|---|---|---|---|---|---|
Capitalization 1 | 0.543 | 0.4879 | 0.181 | 0.2912 | 0.4722 | 0.787 |
Enterprise Value (EV) 1 | 2.236 | 1.974 | 1.865 | 1.699 | 1.971 | 2.35 |
P/E ratio | -1.29 x | 0.62 x | -0.23 x | -0.47 x | -1.87 x | -3.03 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | - | - |
EV / Revenue | - | - | - | - | - | - |
EV / EBITDA | -17 x | -12.8 x | -8.29 x | - | - | - |
EV / FCF | -19.8 x | -13.1 x | 9.91 x | -29.8 x | -182 x | 71.7 x |
FCF Yield | -5.06% | -7.65% | 10.1% | -3.35% | -0.55% | 1.4% |
Price to Book | -0.29 x | -0.53 x | -0.12 x | -0.13 x | -0.19 x | -0.29 x |
Nbr of stocks (in thousands) | 78,696 | 78,696 | 78,696 | 78,696 | 78,696 | 78,696 |
Reference price 2 | 0.006900 | 0.006200 | 0.002300 | 0.003700 | 0.006000 | 0.0100 |
Announcement Date | 17/04/17 | 17/04/18 | 16/04/19 | 14/04/20 | 15/04/21 | 15/04/22 |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
---|---|---|---|---|---|---|
Net sales | - | - | - | - | - | - |
EBITDA 1 | -0.1317 | -0.1543 | -0.225 | - | - | - |
EBIT 1 | -0.1388 | -0.1652 | -0.2359 | -0.2017 | -0.0606 | -0.0434 |
Operating Margin | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -0.398 | 0.8691 | -0.7368 | -0.6219 | -0.2527 | -0.26 |
Net income 1 | -0.398 | 0.8691 | -0.7368 | -0.6219 | -0.2527 | -0.26 |
Net margin | - | - | - | - | - | - |
EPS 2 | -0.005360 | 0.009999 | -0.0100 | -0.007902 | -0.003211 | -0.003304 |
Free Cash Flow 1 | -0.1131 | -0.1509 | 0.1882 | -0.0569 | -0.0108 | 0.0328 |
FCF margin | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 17/04/17 | 17/04/18 | 16/04/19 | 14/04/20 | 15/04/21 | 15/04/22 |
Balance Sheet Analysis
Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
---|---|---|---|---|---|---|
Net Debt 1 | 1.69 | 1.49 | 1.68 | 1.41 | 1.5 | 1.56 |
Net Cash position 1 | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | -12.86 x | -9.627 x | -7.485 x | - | - | - |
Free Cash Flow 1 | -0.11 | -0.15 | 0.19 | -0.06 | -0.01 | 0.03 |
ROE (net income / shareholders' equity) | 25.6% | -71.6% | 65.3% | 34.2% | 11.2% | 10.4% |
ROA (Net income/ Total Assets) | -30.4% | -12.9% | -14.9% | -35.1% | -39.3% | -88.4% |
Assets 1 | 1.31 | -6.75 | 4.93 | 1.774 | 0.6429 | 0.2943 |
Book Value Per Share 2 | -0.0200 | -0.0100 | -0.0200 | -0.0300 | -0.0300 | -0.0300 |
Cash Flow per Share 2 | 0 | 0.0100 | 0 | 0 | 0 | 0 |
Capex | - | - | - | - | - | - |
Capex / Sales | - | - | - | - | - | - |
Announcement Date | 17/04/17 | 17/04/18 | 16/04/19 | 14/04/20 | 15/04/21 | 15/04/22 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
-49.37% | 315K | |
+11.73% | 226B | |
+9.53% | 188B | |
+14.63% | 137B | |
+27.47% | 108B | |
-0.04% | 63.19B | |
+13.73% | 52.26B | |
+4.86% | 51B | |
+7.72% | 43.89B | |
+7.86% | 38.07B |
- Stock Market
- Equities
- QTXB Stock
- Financials QuantRx Biomedical Corporation